semaglutide compounding ending Compounded Semaglutide: Legal & Safe 2026 FDA sets tirzepatide compounding deadlines

Tania, A

Common side effects include: Nausea Vomiting Diarrhea Stomach pain Constipation Reduced appetite More serious risks may involve: Thyroid concerns Pancreatitis Gallbladder issues Vision changes Severe gastrointestinal (GI) complications Allergic reactions A healthcare provider should review your medical history before starting treatment

Schedule Your Consultation Thinking ahead about body contouring

Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023

After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo

For example, Wegovy is specifically FDA-approved for weight management in adults with obesity or overweight conditions